Survey: Less than 10% AEs dubbed "serious;" Crucell lands UNICEF pediatric vaccine order;

> Half of surveyed drugmakers receive more than 1,000 adverse event reports per month; more than half of those report that fewer than 10 percent of their AE reports are serious. Article

> UNICEF has awarded Dutch biopharma Crucell an additional $110 million to supply its liquid pentavalent pediatric vaccine Quinvaxem to the developing world. Release

> In a partnership, Vetter will fill early-stage, high-value biopharmaceuticals at a Skokie, IL, developmental facility slated to open this fall, and Sentry will label, package and ship the clinical supplies from its site in Indianapolis. Article

> JHP Pharmaceuticals' sterile manufacturing site in Rochester, MI, has passed its GMP/pre-approval audit by the FDA drug center, following two thumbs-up last year from the regulator's biologics center and the European Medicines Agency. Release

> DSM Biologics has announced the successful scale up of its yield-boosting XD technology to 50 liters. Announcement